Last reviewed · How we verify
Ribavirin Oral Product
At a glance
| Generic name | Ribavirin Oral Product |
|---|---|
| Also known as | Barivir |
| Sponsor | Zagazig University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ARN-75039 Lassa Fever Treatment in West Africa (PHASE2)
- ISTH/ANRS 0409s INTEGRATE Lassa Fever Study (PHASE2, PHASE3)
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma (PHASE2)
- Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital (PHASE4)
- The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever (PHASE3)
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
- Zepatier in Patients with Substance Use
- The Efficacy of Vosevi in Treating DAA-experienced Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ribavirin Oral Product CI brief — competitive landscape report
- Ribavirin Oral Product updates RSS · CI watch RSS
- Zagazig University portfolio CI